Biomedical Engineering Reference
In-Depth Information
12. Riehemann, K.; Schneider, S. W.; Luger, T. A.; Godin, B.; Ferrari, M.; Fuchs, H. Nanomedicine-
challenge and Perspectives.
Angew. Chem. Int. Ed. Engl.
2009,
48,
872-897.
13. Ferrari, M. Cancer Nanotechnology: Opportunities and Challenges.
Nat. Rev. Cancer
2005,
5,
161-171.
14. Wagner, W.; Dullaart, A.; Bock, A. K.; Zweck, A. The Emerging Nanomedicine Landscape.
Nat. Biotechnol.
2006,
24,
1211-1217.
15. Sanhai, W. R.; Sakamoto, J. H.; Canady, R.; Ferrari, M. Seven Challenges for Nanomedicine.
Nat. Nanotechnol.
2008,
3,
242-244.
16. Torchilin, V. P. Recent Advances with Liposomes as Pharmaceutical Carriers.
Nat. Rev. Drug
Discov.
2005,
4,
145-160.
17. Hashizume, H.; Baluk, P.; Morikawa, S.; McLean, J. W.; Thurston, G.; Roberge, S., et al.
Openings between Defective Endothelial Cells Explain Tumor Vessel Leakiness.
Am.
J. Pathol.
2000,
156,
1363-1380.
18. Maeda, H. The Enhanced Permeability and Retention (EPR) Effect in Tumor Vasculature: The
Key Role of Tumor-Selective Macromolecular Drug Targeting.
Adv. Enzyme Regul.
2001,
41,
189-207.
19. Harris, C. M. Liquid Array Single-handedly Detects Bounty of BW Agents.
Anal. Chem.
2003
.
20. Maeda, H.; Bharate, G. Y.; Daruwalla, J. Polymeric Drugs for Efficient Tumortargeted Drug
Delivery Based on EPR Effect.
Eur. J. Pharm. Biopharm.
2009,
71,
409-419.
21. Duncan, R. Polymer Conjugates as Anticancer Nanomedicines.
Nat. Rev. Cancer
2006,
6,
688-701.
22. Duncan, R. The Dawning era of Polymer Therapeutics.
Nat. Rev. Drug Discov.
2003,
2,
347-360.
23. Akerman, M. E.; Chan, W. C.; Laakkonen, P.; Bhatia, S. N.; Ruoslahti, E. Nanocrystal Target-
ing In vivo.
PNAS U.S.A.
2002,
99,
12617-12621.
24. Ballou, B.; Lagerholm, B. C.; Ernst, L. A.; Bruchez, M. P.; Waggoner, A. S. Noninvasive
Imaging of Quantum Dots in Mice.
Bioconjugate Chem.
2004,
15,
79-86.
25. Dabholkar, R. D.; Sawant, R. M.; Mongayt, D. A. Polyethylene Glycol-phosphatidylethanol-
amine Conjugate (PEG-PE)-based Mixed Micelles: Some Properties, Loading with Paclitaxel,
and Modulation of P-glycoprotein-mediated Efflux.
Int. J. Pharm.
2006,
315,
148-157.
26. Gao, X.; Cui, Y.; Levenson, R. M.; Chung, L. W. K.; Nie, S. In vivo Cancer Targeting and
Imaging with Semiconductor Quantum Dots.
Nat. Biotechnol.
2004,
22,
969-976.
27. Koo, O.; Rubinstein, I.; Onyuksel, H. Camptothecin in Sterically Stabilized Phospholipid
Micelles: A Novel Nanomedicine.
Nanomedicine
2005,
1,
77-84.
28. van Nostrum, C. Polymeric Micelles to Deliver Photosensitizers for Photodynamic Therapy.
Adv. Drug. Delivery Rev.
2004,
56,
9-12.
29. Chauhan, A.; Sridevi, S.; Chalasani, K.; Jain, A.; Jain, S.; Jain, N.; Diwan, P. Dendrimer-medi-
ated Transdermal Delivery: Enhanced Bioavailability of Indomethacin.
J. Controlled Release
2003,
90,
335.
30. Barrett, T.; Ravizzini, G.; Choyke, P.; Kobayashi, H. Dendrimers in Medical Nanotechnology.
IEEE Eng. Med. Biol. Mag.
2009,
28,
12-22.
31. Battah, S.; Balaratnam, S.; Casas, A.; O'Neill, S.; Edwards, C.; Batlle, A.; Dobbin, P.;
MacRobert, A. Macromolecular Delivery of 5-aminolaevulinic Acid for Photodynamic
Therapy Using Dendrimer Conjugates.
Mol. Cancer Ther.
2007,
6,
876.
32. Bharali, D.; Khalil, M.; Gurbuz, M.; Simone, T.; Mousa, S. Nanoparticles and Cancer
Therapy: A Concise Review with Emphasis on Dendrimers.
Int. J. Nanomed.
2009,
4,
1-7.
